Figure 4
From: Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia
The safety of SAMiRNA-AR68. (a) HFDP and HaCaT cells were treated with PBS or the indicated dose of SAMiRNA-AR68 for 72 h. WST-1 assays were performed to measure cell viability. (b) Human PBMCs were treated with 20 μg/ml concanavalin A (ConA) as a positive control, PBS, or the indicated doses of SAMiRNA-AR68 for 6 h. Total RNA extracts were subjected to qPCR assays to evaluate the expression of proinflammatory cytokines, including IL-1β, IL-6, INF-γ and TNF-α, normalized to that of the ribosomal protein L13A (RPL13A) gene.
